|
|
Volumn 316, Issue 5831, 2007, Pages 1550-1551
|
|
Heart attack risk overshadows a popular diabetes therapy
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2,4 THIAZOLIDINEDIONE DERIVATIVE;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
INSULIN;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
PIOGLITAZONE;
ROFECOXIB;
ROSIGLITAZONE;
TRIACYLGLYCEROL;
ANTIDIABETIC AGENT;
ANTIINFLAMMATORY ACTIVITY;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR SYSTEM;
DIABETES MELLITUS;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HEART INFARCTION;
HUMAN;
INTERNATIONAL COOPERATION;
MEDICAL SOCIETY;
NOTE;
PRIORITY JOURNAL;
RISK ASSESSMENT;
ARTICLE;
BLOOD;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
DRUG INDUSTRY;
META ANALYSIS;
RISK;
RISK FACTOR;
CHOLESTEROL, HDL;
CHOLESTEROL, LDL;
CLINICAL TRIALS;
DIABETES MELLITUS;
DRUG INDUSTRY;
HUMANS;
HYPOGLYCEMIC AGENTS;
META-ANALYSIS;
MYOCARDIAL INFARCTION;
RISK;
RISK FACTORS;
THIAZOLIDINEDIONES;
TRIGLYCERIDES;
|
|
EID: 34250847753
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.316.5831.1550 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|